We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Lipid Levels from Non-Fasting Patients Deemed Suitable for Assessing CVD Risk

By LabMedica International staff writers
Posted on 04 Jun 2019
Results published in a recent paper suggested strongly that lipid levels measured in blood samples from non-fasting patients were accurate and predicative of future cardiovascular risk.

A team of investigators from Brigham and Women's Hospital (Boston, MA, USA), Harvard Medical School (Boston, MA, USA), and Imperial College London (United Kingdom) sought to determine how non-fasting lipid levels compared with fasting lipid levels measured in the same individuals for assessing cardiovascular risk, and what was their association with incident cardiovascular events.

To this end they performed a secondary analysis of the results of a randomized clinical trial that included 8270 of 10,305 participants from the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA) with non-fasting and fasting lipid levels measured four weeks apart (including 6855 participants with no prior vascular disease). More...
Data were collected from February 1, 1998, to December 31, 2002, and analyzed from February 1, 2016, to November 30, 2018.

Analysis of the results revealed that among the 8270 participants (82.1% male; mean age, 63.4 years), non-fasting samples had modestly higher triglyceride levels and similar cholesterol levels compared to fasting samples. Associations of non-fasting lipid levels with coronary events were similar to those for fasting lipid levels.

"We hope this study will be the final nail in the coffin, providing strong evidence that, within the same person, fasting or not before a lipid level test does not matter for predicting cardiovascular risk," said senior author Dr. Samia Mora, director of the center for lipid metabolomics at Brigham and Women's Hospital. "This should reassure health care providers and patients that it does not make a difference if you fast or do not fast if the goal is to predict your cardiovascular risk."

"We spend most of our lives in a non-fasting state. And for some patients, especially those who are elderly or have diabetes, it can be risky to fast before lipid testing," said Dr. Mora. "Health care providers held back because of concerns of variability within individuals, but the data here is so convincing. It should allow people to feel more comfortable with non-fasting lipid testing for cardiovascular risk assessment, including when taking a statin."

The paper was published in the May 28, 2019, online edition of the journal JAMA Internal Medicine.

Related Links:
Brigham and Women's Hospital
Harvard Medical School
Imperial College London

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
New
Drug Testing Assays
Atellica DT 250 Analyzer
New
Slide Scanner System
NanoZoomer S540MD
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.